ResearchDx, a contract diagnostics organization for the biopharmaceutical and diagnostic industries, and CompanDX, a molecular diagnostics company focused on biomarker discovery, have entered into a strategic partnership to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process.
From initial assay conceptualization, discovery, optimization and validation in a CAP/CLIA laboratory environment, through a complete set of clinical research services and on to regulatory approval, ResearchDx’s primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting.
CompanDX uses ‘Distiller’ bioinformatics platform to derive small composite biomarker panels from complex data of high dimensionality for the clinical development of therapeutics.
The collaboration is expected to allow clients to initiate the parallel development of companion diagnostic tests from the earliest stages of drug development.
CompanDX CEO Andy Sutton said they are thrilled to dovetail into ResearchDx’s downstream delivery by providing the biomarkers tailored to client’s drug candidates that will form the basis of validated tests for use in the clinic.